Silo Pharma Advances Canadian Patent for PTSD Therapy
SARASOTA, Fla., August 18, 2026 Silo Pharma, Inc. announced that the Canadian Intellectual Property Office (CIPO) has issued a...
CNS Therapeutics
Advertisement
Nona, Lonza Partner on BBB Technology for CNS Therapies
CAMBRIDGE, Massachusetts, July 1, 2026 Nona Biosciences has entered into a strategic collaboration with Lonza to develop a next-generation...
BioArctic, Lilly Partner on Next-Gen Brain Therapies
STOCKHOLM, Sweden, June 22, 2026 BioArctic AB and Eli Lilly and Company have entered into a major research and...
Insilico Medicine and SK Bio Launch $2.5B CNS Alliance
BOSTON, MA and SEOUL, South Korea, June 22 2026 Insilico Medicine and SK Biopharmaceuticals have announced a landmark artificial...
Teva Advances Schizophrenia Therapy in Europe
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
Advertisements
Fosun Pharma Signs Global Option Deal for AriBio’s AR1001
SHANGHAI and SEONGNAM-SI, South Korea, May 13, 2026 Fosun Pharma and AriBio announced the signing of an exclusive global...
AI Drug Discovery Deal Expands CNS Pipeline Value
Hong Kong | March 30, 2026 AI Collaboration Accelerates CNS Drug Discovery Insilico Medicine and Tenacia Biotechnology have announced...
Lupin Launches Topiramate ER Capsules in United States
MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 — Global pharmaceutical company Lupin Limited announced the U.S. launch of...
Contineum Secures $90M Funding to Advance CNS Drug Pipeline
BOSTON, December 12, 2025 — Contineum Therapeutics, Inc. announced the pricing of an upsized $90.0 million public offering of...
FDA Clears Path Forward for Vanda’s Motion-Sickness Drug Development
WASHINGTON, D.C., December 4, 2025 — The U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold...
Advertisement
